Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Operating Expenses (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Operating Expenses data on record, last reported at $45.7 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 27.98% year-over-year to $45.7 million; the TTM value through Sep 2025 reached $173.0 million, up 20.2%, while the annual FY2024 figure was $156.7 million, 9.37% up from the prior year.
  • Operating Expenses reached $45.7 million in Q3 2025 per GLUE's latest filing, up from $38.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $47.6 million in Q4 2024 and bottomed at $34.3 million in Q1 2023.
  • Average Operating Expenses over 3 years is $38.7 million, with a median of $37.2 million recorded in 2023.
  • The widest YoY moves for Operating Expenses: up 36.66% in 2024, down 3.31% in 2024.
  • A 3-year view of Operating Expenses shows it stood at $34.9 million in 2023, then surged by 36.66% to $47.6 million in 2024, then decreased by 3.99% to $45.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $45.7 million in Q3 2025, $38.7 million in Q2 2025, and $40.9 million in Q1 2025.